Search results
People living with sight loss in Scotland are able to benefit from free ferry travel for their companion when travelling with Caledonian MacBrayne (CalMac) Ferries with the NEC+1 card. The ferries operate across Scotland’s islands.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Catherine L’Estrange, aged 11 from London has become the first individual in the UK to receive an investigative gene therapy treatment for retinal dystrophy associated with the BBS10 gene.
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
The latest research news from Retina UK.
This is the final edition of Look Forward this year and what a year it has been! We’ve had some very positive feedback about our Conferences and the Big Give Christmas Challenge is back - a great opportunity to double your donation at no extra cost to you! We’ve included a handy ‘What’s on’ article which outlines some of our plans for 2026. We would like to take this opportunity to wish all of our readers a very Merry Christmas and a happy and fulfilling New Year.
The latest research news piece from Retina UK.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
